Kopp Investment Advisors LLC increased its holdings in AtriCure Inc. (NASDAQ:ATRC) by 11.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,435 shares of the medical device company’s stock after buying an additional 12,836 shares during the period. AtriCure accounts for 2.3% of Kopp Investment Advisors LLC’s holdings, making the stock its 16th largest position. Kopp Investment Advisors LLC owned 0.37% of AtriCure worth $2,324,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. California Public Employees Retirement System raised its position in shares of AtriCure by 4.3% in the second quarter. California Public Employees Retirement System now owns 36,100 shares of the medical device company’s stock valued at $875,000 after buying an additional 1,500 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in AtriCure by 1.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 173,033 shares of the medical device company’s stock valued at $3,157,000 after acquiring an additional 2,932 shares during the last quarter. Macquarie Group Ltd. increased its stake in AtriCure by 3.9% in the third quarter. Macquarie Group Ltd. now owns 82,245 shares of the medical device company’s stock valued at $1,840,000 after acquiring an additional 3,056 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in AtriCure by 2.4% in the fourth quarter. Essex Investment Management Co. LLC now owns 145,258 shares of the medical device company’s stock valued at $2,650,000 after acquiring an additional 3,460 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in AtriCure by 1.8% in the third quarter. Bank of New York Mellon Corp now owns 203,273 shares of the medical device company’s stock valued at $4,547,000 after acquiring an additional 3,580 shares during the last quarter. Institutional investors own 87.50% of the company’s stock.
A number of research analysts recently issued reports on the stock. BidaskClub raised shares of AtriCure from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 15th. Canaccord Genuity lifted their price objective on shares of AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. TheStreet cut shares of AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. ValuEngine cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective (down from $25.00) on shares of AtriCure in a research note on Tuesday, January 16th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AtriCure currently has an average rating of “Buy” and a consensus price target of $24.67.
Shares of AtriCure Inc. (ATRC) opened at $19.65 on Monday. AtriCure Inc. has a one year low of $14.88 and a one year high of $25.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.87 and a current ratio of 2.58.
AtriCure (NASDAQ:ATRC) last posted its earnings results on Monday, February 26th. The medical device company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. The firm had revenue of $46.06 million for the quarter, compared to analysts’ expectations of $45.85 million. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. The company’s revenue was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. equities analysts forecast that AtriCure Inc. will post -0.83 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Kopp Investment Advisors LLC Has $2.32 Million Stake in AtriCure Inc. (ATRC)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/12/kopp-investment-advisors-llc-has-2-32-million-stake-in-atricure-inc-atrc.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.